Featured projects

Heterogeneidad intra-tumoral e impacto clínico en cáncer de mama precoz HER2-positivo y triple-negativo

Principal investigator: Aleix Prat Aparicio.
Funder: Instituto de Salud Carlos III .

Code: PI22/01017.

Duration: 01/01/2023 - 31/12/2025
HOPE: Real World clinical practice study to assess the impact of using comprehensive genomic data on the next treatment decision making choice in patients with locally advanced or metastatic breast cancer in Spain.

Principal investigator: Aleix Prat Aparicio.
Funder: Grupo SOLTI .

Code: SOLTI-1903 HOPE.

Duration: 31/03/2021
Predicción de beneficio a inhibidores de CDK4/6 y tratamiento endocrino en cáncer de mama metastásico, receptor hormonal positivo/HER2 negativo.

Principal investigator: Aleix Prat Aparicio.
Funder: SEOM (Sociedad Española Oncología Médica) .

Code: SEOM_CANCERMAMA20_01.

Duration: 15/01/2021 - 14/01/2022

Web: https://seom.org/apoyo-a-la-investigacion/premios-becas-seom/resoluciones/208212-fallo-becas-seom-2020
A European Cancer Image Platform Linked to Biological and Health Data for Next-Generation Artificial Intelligence and Precision Medicine in Oncology

Principal investigator: Jordi Rimola Gibert, Aleix Prat Aparicio.
Funder: European Commission .

Code: CE_H2020_SC1_20_1s13.

Duration: 01/10/2020 - 30/09/2024
RESCUER: Resistance Under Combinatorial Treatment in ER+ and ER- Breast Cancer.

Principal investigator: Aleix Prat Aparicio, Antoni Hurtado Rodríguez.
Funder: European Commission .

Code: H2020-SC1-BHC-02-2019 / 847912-2.

Duration: 01/01/2020 - 31/12/2024
Adoptive cell therapy using CD3+/PD1+ tumor infiltrating lymphocytes in patients with advanced breast cancer

Principal investigator: Aleix Prat Aparicio.
Funder: Asociación Española Contra el Cáncer .

Code: GCAEC19010PRAT.

Duration: 01/12/2019 - 30/11/2024
Targeting the HER2-enriched phenotype in hormone receptor-positive breast cancer

Principal investigator: Aleix Prat Aparicio.
Funder: Instituto de Salud Carlos III .

Code: INT_BCN_Catalyst_18.

Duration: 01/03/2019 - 28/02/2023
Prospective exploratory study for determination of circulating tumor DNA (ctDNA) in blood samples from patients treated for breast cancer in follow-up and without evidence of relapse (B-CRONOS).

Principal investigator: Aleix Prat Aparicio.
Funder: Fundación Quirón Salud .

Code: FQuironSalud_Mama18.

Duration: 11/02/2019 - 10/02/2022
Estudio prospectivo exploratorio para la determinación de DNA circulante tumoral (ctDNA) en muestras sanguíneas de pacientes tratadas por cáncer de mama en seguimiento y sin evidencia de recidiva: ESTUDIO B-CRONOS

Principal investigator: Aleix Prat Aparicio.
Funder: CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER (Sede o evento); Fundación Mutua Madrileña .

Code: AP168952018.

Duration: 15/06/2018 - 14/06/2021
AECC 2017 Predictores moleculares de la respuesta al doble bloqueo de HER2 sin quimioterapia en el cancer de mama HER2-positivo

Principal investigator: Aleix Prat Aparicio.
Funder: Institut d`Investigacions Biomèdiques August Pi i Sunyer (Sede o evento); Asociación Española Contra el Cáncer .

Duration: 01/11/2017 - 31/12/2019

The research of this group can be carried out thanks to the funders.

Donations that make possible the research of this group.

Featured projects

Heterogeneidad intra-tumoral e impacto clínico en cáncer de mama precoz HER2-positivo y triple-negativo

HOPE: Real World clinical practice study to assess the impact of using comprehensive genomic data on the next treatment decision making choice in patients with locally advanced or metastatic breast cancer in Spain.

Predicción de beneficio a inhibidores de CDK4/6 y tratamiento endocrino en cáncer de mama metastásico, receptor hormonal positivo/HER2 negativo.

A European Cancer Image Platform Linked to Biological and Health Data for Next-Generation Artificial Intelligence and Precision Medicine in Oncology

RESCUER: Resistance Under Combinatorial Treatment in ER+ and ER- Breast Cancer.

Adoptive cell therapy using CD3+/PD1+ tumor infiltrating lymphocytes in patients with advanced breast cancer

Targeting the HER2-enriched phenotype in hormone receptor-positive breast cancer

Prospective exploratory study for determination of circulating tumor DNA (ctDNA) in blood samples from patients treated for breast cancer in follow-up and without evidence of relapse (B-CRONOS).

Estudio prospectivo exploratorio para la determinación de DNA circulante tumoral (ctDNA) en muestras sanguíneas de pacientes tratadas por cáncer de mama en seguimiento y sin evidencia de recidiva: ESTUDIO B-CRONOS

AECC 2017 Predictores moleculares de la respuesta al doble bloqueo de HER2 sin quimioterapia en el cancer de mama HER2-positivo

Major founders

Contributors